PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Journal of Diabetes and its Complications0 citationsOpen Access

Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY

View Full Paper
RWRobert WeingoldGFGerasimos FilippatosSAStefan D. Anker

Key Points

  • Finerenone improves KDIGO risk category for renal function in patients with CKD and type 2 diabetes.
  • Specifically, individuals treated with finerenone had a notable improvement in outcomes related to chronic kidney disease.

Structured PICO

Does finerenone improve KDIGO risk category in patients with CKD and type 2 diabetes?

P
Population
Patients with CKD and type 2 diabetes
I
Intervention
Finerenone
O
Outcome
Improved KDIGO risk categorysurrogate

Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes.

Abstract

FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) are registered with ClinicalTrials.gov (funded by Bayer AG).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Weingold et al. (2026) studied this question.

synapsesocial.com/papers/69a75ed6c6e9836116a29cdbhttps://doi.org/10.1016/j.jdiacomp.2026.109274
Ask AI
Helpful
Bookmark
Share
View Full Paper